| 词条 | Bemcentinib |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = 1-(6,7-Dihydro-5H-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-N-[(7S)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine | image = Bemcentinib.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Investigational | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1037624-75-1 | class = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 46215462 | DrugBank = | UNII = 0ICW2LX8AS | KEGG = D11438 | synonyms = BGB324; R428 | C=30|H=34|N=8 }} Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase.[1] Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics. FunctionBemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumor cells, leading to aggressive metastatic cancers.[2][3] In addition, BGB324 enhances sensitivity to various therapies including chemotherapy, immunotherapy and several targeted therapeutics.[4] Clinical trialsBemcentinib is currently undergoing Phase II clinical trials for non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), acute myeloid leukemia /myelodysplastic syndrome (AML/MDS), melanoma and metastatic pancreatic cancer. References1. ^{{cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=771720 | title= Definition of AXL inhibitor BGB324 | work = NCI Drug Dictionary | publisher = National Cancer Institute}} 2. ^Gay, Carl M; Balaji, Kavitha; Byers, Lauren Averett (2017). "Giving AXL the axe: targeting AXL in human malignancy". British Journal of Cancer. 116 (4): 415–423. 3. ^Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B (2014). "AXL kinase as a novel target for cancer therapy". Oncotarget. 5 (20): 9546–63 4. ^Davidsen, Kjersti T.; Haaland, Gry S.; Lie, Maria K.; Lorens, James B. (2017). The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance. In: Akslen L., Watnick R. (eds) Biomarkers of the Tumor Microenvironment. Springer, Cham. pp. 351–376. 4 : Experimental cancer drugs|Pyrrolidines|Triazoles|Protein kinase inhibitors |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。